MedPath

Tagged News

Sofinnova Partners and NVIDIA Launch AI Infrastructure Partnership to Accelerate European Life Sciences Innovation

AIDrug DiscoveryPrecision Medicine
  • Sofinnova Partners, a leading European life sciences venture capital firm, has partnered with NVIDIA to provide GPU credits and high-performance AI infrastructure to its portfolio companies through NVIDIA DGX Cloud Lepton.
  • Four promising European digital medicine startups—BioCorteX, Bioptimus, Cure51, and Latent Labs—are among the first cohort to gain access to NVIDIA's computational resources, enabling faster biological data processing and model development.
  • Cure51 demonstrated the partnership's potential by achieving up to 17x faster genomic processing and more than 2x cost savings using NVIDIA's GPU-accelerated genomics toolkit compared to traditional CPU methods.
  • The collaboration aims to position Europe at the forefront of AI-driven drug discovery by providing startups with computational power comparable to Silicon Valley tech giants in the $100B+ life sciences market.

Elkedonia Raises €11.25 Million to Develop Novel Neuroplastogen Therapy for Treatment-Resistant Depression

Precision Medicine
  • Elkedonia closed an oversubscribed €11.25 million seed funding round to advance first-in-class neuroplastogen therapeutics targeting the Elk1 protein for treatment-resistant depression.
  • The company's approach targets neuroplasticity restoration without the side effects of psychedelics or ketamine, addressing the needs of approximately 100 million patients globally who don't respond to current treatments.
  • The Franco-Belgian startup leverages research from Sorbonne University and plans to develop precision medicine biomarkers alongside small molecule inhibitors of the intracellular Elk1 target.
  • Major depressive disorder affects 300 million people worldwide, with suicide being the third leading cause of death among 15-29 year-olds, highlighting the urgent need for innovative therapeutic solutions.

Cogent Biosciences Secures $400M Debt Financing to Advance Bezuclastinib Through Pivotal Trials

Precision MedicineRare Disease
  • Cogent Biosciences secured a $400 million non-dilutive debt financing facility with SLR Capital Partners, with an initial $50 million already drawn to support the company's growth strategy.
  • The company is on track to report results from three pivotal bezuclastinib trials in 2025, starting with SUMMIT results in July for NonAdvSM patients.
  • Additional funding tranches are tied to clinical milestones, with $100 million available upon successful SUMMIT and PEAK trial readouts and commercial success.
  • The financing enhances Cogent's financial flexibility as it prepares for the expected bezuclastinib launch in 2026 for genetically defined diseases.

Bayer and Broad Institute Extend Cardiovascular Research Partnership Through 2030

Precision MedicineDrug Discovery
  • Bayer and the Broad Institute have extended their decade-long cardiovascular research collaboration by an additional five years, focusing on precision cardiology target identification and novel therapeutic approaches.
  • The partnership has already yielded clinical progress with Bayer's GIRK4 inhibitor entering Phase I trials in May 2025 for atrial fibrillation treatment.
  • Current research efforts target specific cardiovascular conditions including dilated cardiomyopathy, leveraging genomics expertise and human cardiomyocyte platforms for drug discovery.
  • The collaboration combines Broad Institute's genomics capabilities with Bayer's drug discovery experience to address significant unmet medical needs in cardiovascular diseases.

GenePoweRx Partners with MGI Tech to Advance AI-Powered Genomic Solutions for Personalized Medicine

AIPrecision Medicine
  • GenePoweRx, an Indian AI-driven personalized medicine startup, has formed a strategic co-marketing partnership with China-based MGI Tech to deliver AI-powered genomic solutions for predictive healthcare and precision medicine.
  • The collaboration integrates MGI's robust sequencing platforms with GenePoweRx's advanced bioinformatics and AI engine to provide rapid, accurate, and clinical-grade genomic services to individuals and institutions worldwide.
  • The partnership aims to democratize access to advanced healthcare technologies by embedding precision genomics into everyday medical decision-making and making personalized preventive healthcare more accessible and actionable.

Antares Therapeutics Launches with $177 Million Series A to Advance First-in-Class Cancer Precision Medicines

Precision MedicineOncology
  • Antares Therapeutics launched with $177 million in Series A financing co-led by five major healthcare investment firms to develop first-in-class precision medicines for cancer and other serious diseases.
  • The company is a spin-out of Scorpion Therapeutics, which recently sold its PI3Kα inhibitor program STX-478 to Eli Lilly for up to $2.5 billion in March 2025.
  • Led by Scorpion's former executive team, Antares plans to advance its first new product candidate into clinical trials in 2026, focusing on previously undruggable targets including transcription factors.
  • Pierre Fabre Laboratories acquired global rights to two clinical-stage mutant EGFR inhibitor programs for non-small cell lung cancer treatment from the company's pipeline.

Nordic Capital Invests in Minerva Imaging to Build Global Radiopharmaceutical Platform

Targeted TherapyPrecision MedicineOncology
  • Nordic Capital has announced a strategic investment in Minerva Imaging, a Denmark-based contract research organization specializing in targeted radioligand therapies for cancer treatment.
  • The partnership aims to accelerate Minerva's international expansion and strengthen its integrated platform serving pharmaceutical and biotechnology companies in radiopharmaceutical development.
  • Minerva reported revenue of more than DKK 225 million ($35 million) in 2024 and employs over 150 professionals, including PhD-level scientists at its Copenhagen headquarters.
  • The global radiopharmaceuticals market is positioned for significant growth driven by increasing cancer incidence and growing demand for precision medicines.

Novel Therapeutic Classes Transform Future Treatment Paradigm for Metastatic Castration-Resistant Prostate Cancer

Precision Medicine
  • The future of metastatic castration-resistant prostate cancer (mCRPC) treatment is evolving with novel drug classes including radioligand therapies, PROTACs, and immunotherapy approaches showing promising clinical potential.
  • Precision medicine approaches utilizing comprehensive tumor sequencing will enable personalized combination regimens targeting specific mutations and surface proteins to maximize effectiveness while reducing adverse effects.
  • Treatment selection increasingly depends on prior androgen receptor pathway inhibitor (ARPI) exposure, with ARPI-naive patients representing a substantial portion in community settings who may benefit from these agents at mCRPC diagnosis.
  • The ultimate goal is achieving durable disease control through rational combinations that allow longer treatment breaks and reduced medical facility time while preserving patient independence and quality of life.

Sequencing Abiraterone and Enzalutamide in mCRPC

NCT02125357CompletedPhase 2
British Columbia Cancer Agency
Posted 9/1/2014

A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

NCT06551324RecruitingPhase 3
Pfizer
Posted 10/21/2024

Mevrometostat Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

NCT03460977RecruitingPhase 1
Pfizer
Posted 4/17/2018

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

NCT06629779RecruitingPhase 3
Pfizer
Posted 10/22/2024

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer

NCT03748641Active, Not RecruitingPhase 3
Janssen Research & Development, LLC
Posted 1/25/2019

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

NCT03732820Active, Not RecruitingPhase 3
AstraZeneca
Posted 10/31/2018

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

NCT03395197Active, Not RecruitingPhase 3
Pfizer
Posted 12/18/2017

First Ascent Biomedical Partners with Fight Colorectal Cancer for $350,000 Precision Medicine Study

Precision MedicineAI
  • First Ascent Biomedical and Fight Colorectal Cancer have launched a $350,000 prospective feasibility study to advance precision oncology for colorectal cancer patients using xDRIVE tumor profiling technology.
  • The study will enroll 25 patients with metastatic colorectal cancer in Minnesota, integrating functional drug testing, genetic analysis, and artificial intelligence to provide personalized treatment insights.
  • Led by gastrointestinal cancer specialist Dr. Hao Xie and principal investigator Dr. Noah Berlow, the study aims to complete enrollment within nine months and deliver actionable data to oncologists.
  • The collaboration represents a strategic focus on enhancing care for patients with limited treatment options through advanced research and rapid, individualized tumor profiling.

Denovo Biopharma Forms Neuroscience Advisory Board to Advance Precision Medicine Approach for Treatment-Resistant Depression

Precision MedicineAI
  • Denovo Biopharma has established a neuroscience Scientific Advisory Board chaired by Dr. Charles B. Nemeroff to guide development of its Phase 3-ready biomarker-guided depression therapy DB104.
  • The company's lead asset liafensine is a first-in-class triple reuptake inhibitor that targets serotonin, norepinephrine, and dopamine transporters for treatment-resistant depression.
  • Denovo's AI-based platform identified a novel genetic biomarker at the ANK3 gene that correlates with liafensine efficacy, representing the first genetic biomarker validated in psychiatry.
  • The advisory board includes industry veterans with experience developing major CNS treatments including Cymbalta, Trintellix, and Cobenfy for schizophrenia.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy